Eugene Pacelli Mccague Sells 841 Shares of Icon (NASDAQ:ICLR) Stock

Icon Plc (NASDAQ:ICLR) Director Eugene Pacelli Mccague sold 841 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $138,167.89. Following the transaction, the director owned 3,811 shares of the company’s stock, valued at approximately $626,109.19. This trade represents a 18.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Up 0.2%

Shares of NASDAQ:ICLR opened at $167.48 on Friday. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23. The company has a fifty day simple moving average of $162.22 and a 200 day simple moving average of $134.04. The firm has a market cap of $12.82 billion, a PE ratio of 39.31, a price-to-earnings-growth ratio of 6.93 and a beta of 1.21. Icon Plc has a 12-month low of $66.57 and a 12-month high of $203.91.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. During the same period in the prior year, the company posted $3.26 earnings per share. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. On average, equities research analysts anticipate that Icon Plc will post 9.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on ICLR. Piper Sandler cut shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. Citigroup boosted their price objective on Icon from $165.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 31st. DA Davidson set a $164.00 price objective on Icon in a research note on Monday, June 1st. Leerink Partners set a $145.00 target price on Icon in a research report on Thursday, May 28th. Finally, Robert W. Baird set a $194.00 price target on Icon in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Icon presently has a consensus rating of “Hold” and an average price target of $170.40.

Institutional Investors Weigh In On Icon

A number of institutional investors have recently modified their holdings of ICLR. Harris Associates L P acquired a new stake in Icon during the second quarter worth about $238,256,000. Capital World Investors boosted its stake in Icon by 555.2% in the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock valued at $272,688,000 after acquiring an additional 1,268,095 shares during the period. Wellington Management Group LLP grew its holdings in shares of Icon by 26.6% during the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after purchasing an additional 975,268 shares during the last quarter. Lyrical Asset Management LP bought a new position in shares of Icon during the fourth quarter valued at approximately $176,382,000. Finally, Norges Bank acquired a new stake in shares of Icon during the 4th quarter worth approximately $160,073,000. Institutional investors own 95.61% of the company’s stock.

Icon News Summary

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue of $2.06 billion topped estimates of $2.00 billion. Revenue also rose 2.3% year over year, indicating continued demand for its outsourced clinical-research services.
• Positive Sentiment: Analyst support remains a potential catalyst. BMO Capital Markets raised its price target to $187, Mizuho lifted its target to $190, and William Blair upgraded the stock to “strong buy.” The broader analyst consensus is “Hold,” with an average target of $170.40. Analyst coverage article
• Positive Sentiment: Institutional ownership is high at 95.61%, and several investment firms recently initiated or increased positions in ICLR. The stock is also trading above its 50-day and 200-day moving averages, reflecting favorable recent momentum.
• Neutral Sentiment: CEO Barry Balfe, CFO Nigel Clerkin and several directors sold shares totaling roughly $1.6 million at prices near $164.07–$164.29. The filings state that the sales were made to cover tax-withholding obligations connected with vested equity awards, and the insiders retained shares afterward, reducing the negative signal. Icon insider sales article
• Negative Sentiment: Although revenue beat estimates, quarterly EPS fell from $3.26 in the prior-year period, highlighting earnings pressure. ICLR also trades at a relatively demanding valuation, with a price-to-earnings ratio near 39 and a PEG ratio above 6, leaving the stock vulnerable if growth or guidance weakens.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.